The global cell culture market was valued at around US$ 13,000.0 Mn in 2016 and is anticipated to register a stable CAGR of over 9.5% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled “Cell Culture Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.
Publisher's latest report, "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design" provides an in-depth assessment of the current trends in the global biosimilars market, with a particular focus on manufacturing complexities and the strategies being implemented to overcome them.
Orbisresearch.com has announced the addition of the “Global Biosimilar Pipeline Market Research Report 2017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification.
An increase in the aging population, rising incidences of various diseases and increasing pressure to cut healthcare costs are driving explosive growth of the biosimilars market, according to a report by BCC Research.
JHL Biotech announced today that the China Food and Drug Administration (CFDA) has accepted for review JHL's Clinical Trial Application for a proposed bevacizumab biosimilar, JHL1149, to treat cancer.
The biosimilars market is expected to reach USD 23.63 billion by 2023 from USD 5.95 billion in 2018, at a CAGR of 31.7%. Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness, rising incidence of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.
MilliporeSigma recently announced a partnership with Oxford University’s Jenner Institute to develop more robust and scalable vaccine manufacturing processes.
Fujifilm Kyowa Kirin Biologics Co., Ltd. recently announced the company will partner with Mylan N.V. to commercialize FKB327, a biosimilar to Humira (adalimumab) developed by Fujifilm Kyowa Kirin Biologics.
Biogen Inc. and its partner Samsung Bioepis announced recently an agreement with AbbVie for the commercialization of IMRALDI, a biosimilar referencing HUMIRA (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and Biogen and Samsung Bioepis will make royalty payments to AbbVie.
Biosimilars are replicas of the innovator biopharmaceuticals. They offer the advantage of being less expensive as compared to their expensive counterparts.
|
|
|
|
|
|
|
|
|